open access

Vol 12, No 1 (2017)
Review Papers
Published online: 2017-03-03
Get Citation

Edoksaban — another NOAC in the armamentarium of anticoagulants — how it differs from the others? The results of clinical trials of edoxaban

Olga Elżbieta Jelonek, Iwona Gorczyca-Michta, Beata Wożakowska-Kapłon
DOI: 10.5603/FC.2017.0006
·
Folia Cardiologica 2017;12(1):61-67.

open access

Vol 12, No 1 (2017)
Review Papers
Published online: 2017-03-03

Abstract

Non-vitamin K oral antagonist anticoagulants (NOAC) demonstrated efficiency and safety in several clinical trials. These drugs are a promising alternative to standard anticoagulation therapy. One of them is edoxaban — highly selective, reversible and direct inhibitor of factor Xa. It can be used in states that require anticoagulant prophylaxis and treatment, such as prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. The following article presents an analysis of clinical trials conducted to evaluate safety and efficiency of edoxaban.

Abstract

Non-vitamin K oral antagonist anticoagulants (NOAC) demonstrated efficiency and safety in several clinical trials. These drugs are a promising alternative to standard anticoagulation therapy. One of them is edoxaban — highly selective, reversible and direct inhibitor of factor Xa. It can be used in states that require anticoagulant prophylaxis and treatment, such as prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. The following article presents an analysis of clinical trials conducted to evaluate safety and efficiency of edoxaban.

Get Citation

Keywords

non-vitamin K antagonist oral anticoagulants, edoxaban, warfarin, atrial fibrillation, venous thromboembolism

About this article
Title

Edoksaban — another NOAC in the armamentarium of anticoagulants — how it differs from the others? The results of clinical trials of edoxaban

Journal

Folia Cardiologica

Issue

Vol 12, No 1 (2017)

Pages

61-67

Published online

2017-03-03

DOI

10.5603/FC.2017.0006

Bibliographic record

Folia Cardiologica 2017;12(1):61-67.

Keywords

non-vitamin K antagonist oral anticoagulants
edoxaban
warfarin
atrial fibrillation
venous thromboembolism

Authors

Olga Elżbieta Jelonek
Iwona Gorczyca-Michta
Beata Wożakowska-Kapłon

References (13)
  1. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; 160(4): 635–641.
  2. Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014; 74(11): 1209–1231.
  3. Link MS, Giugliano RP, Ruff CT, et al. ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.
  4. O'Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. Eur Heart J. 2015; 36(23): 1470–1477.
  5. Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015; 36(33): 2239–2245.
  6. Goette A, Merino JL, Ezekowitz MD, et al. ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016; 388(10055): 1995–2003.
  7. Lip GYH, Merino J, Ezekowitz M, et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J. 2015; 169(5): 597–604.e5.
  8. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406–1415.
  9. Fuji T, Fujita S, Kawai Y, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J. 2015; 13: 27.
  10. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383(9921): 955–962.
  11. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2016 [Epub ahead of print].
  12. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2016 [Epub ahead of print].
  13. Lip GYH, Lane DA. Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors. J Am Coll Cardiol. 2015; 66(21): 2282–2284.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl